TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03278613

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ES-130
Description: The ES-130 device will be used for the indication of Posterior Tibial Nerve Stimulation for the treatment of fecal incontinence using the FDA-approved protocol for treatment of urge urinary incontinence (UUI) in the PFDN NOTABLe study. There is no PTNS device cleared by the FDA for the indication of FI treatment; therefore, this is considered an investigational device.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: ES-130
Description: The ES-130 device will be used for the indication of Posterior Tibial Nerve Stimulation for the treatment of fecal incontinence using the FDA-approved protocol for treatment of urge urinary incontinence (UUI) in the PFDN NOTABLe study. There is no PTNS device cleared by the FDA for the indication of FI treatment; therefore, this is considered an investigational device.
Study: NCT04607564

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ntombi Vimbela! intervention
Description: Ntombi Vimbela! constitutes a series of ten workshops running for a total 35 hours. The intervention is designed to raise awareness about sexual rights, violence against women and girls and its drivers; sensitise about gender inequality and build more gender equitable beliefs; sensitise about sexual assault; equip participants with skills to assess and act in situations where there is a high risk of sexual assault; build resilience and skills to withstand social and material pressures in college or university ; enable utilisation of health, psycho-social services and access to justice for survivors; enhance communication skills and building healthy sexual relationships; promote mental health and coping and build empathy towards survivors.
Study: NCT02926157

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Life Style and Sleep Intervention
Study: NCT03197038

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Partially supervised home-based walking exercise
Description: Participants will be asked to exercise at home by walking at a moderate intensity. Each participant will receive an exercise prescription. Participants will receive a heart rate monitor. The heart rate monitors will be used to achieve a desired exercise intensity and to monitor adherence levels. The participants will receive biweekly to weekly phone calls, and monthly in person meetings will be used to address any barriers, provide encouragement, and progress the exercise.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Participants will be asked to exercise at home by walking at a moderate intensity. The participants will receive biweekly phone calls, but will not receive a heart rate monitor, individual exercise prescription, or meet with the investigators monthly.
Study: NCT02414243

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: New Amino Acid formula
Description: Ordesa's Amino-Acid based Infant Formula

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Commercially available Amino Acid Formula
Description: Commercially available Amino Acid Formula
Study: NCT01413126

Intervention type: DIETARY_SUPPLEMENT
Group type: NO_INTERVENTION
Intervention: Whole peanuts without skins, Peanut butter, or no peanuts (control)
Description: In accordance with the Food and Drug Administration qualified health claim regarding daily nut intake, 42.5 g of whole peanuts or peanut butter were added to a 75g available carbohydrate-matched breakfast meal each test session.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whole peanuts without skins, Peanut butter, or no peanuts (control)
Description: In accordance with the Food and Drug Administration qualified health claim regarding daily nut intake, 42.5 g of whole peanuts or peanut butter were added to a 75g available carbohydrate-matched breakfast meal each test session.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whole peanuts without skins, Peanut butter, or no peanuts (control)
Description: In accordance with the Food and Drug Administration qualified health claim regarding daily nut intake, 42.5 g of whole peanuts or peanut butter were added to a 75g available carbohydrate-matched breakfast meal each test session.
Study: NCT03433196

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-25 and Atorvastatin
Description: HS-25 20mg (2 tablets), Atorvastatin 10mg, Placebo of Atorvastatin 1 tablet oral, once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: Atorvastatin 20mg (2 tablets), Placebo of HS-25 2 tablets, oral, once daily
Study: NCT00789841

Intervention type: DEVICE
Intervention: Magnetic Tracking System (MTS) and radio-opaque markers
Description: MTS: A small magnetic pill (6x15mm) is swallowed by the patient and the movement of this pill is registered by a sensor (coordinates x,y,z angles θ, φ) and depicted af graphs on a computer screen. For determination of GITT a capsule containing 10 radio-opaque markers is ingested every day for six days, on day seven an abdominal x-ray is performed.
Study: NCT02281435

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PrePex™ device
Description: PrePex™ device for adult male circumcision. The PrePex™ device facilitates adult male circumcision that is bloodless with no anesthesia and no sutures, but in this study the procedure consist an incision on to the foreskin.
Study: NCT02659410

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heat stress (21)
Description: 4h exposure to heat (WBGT of 21°C), no solvent

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heat stress (25)
Description: 4h exposure to heat (WBGT of 25°C), no solvent

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heat stress (30)
Description: 4h exposure to heat (WBGT of 30°C), no solvent

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heat Stress (21) +TOL
Description: 4h exposure to heat (WBGT of 21°C) + Toluene (concentration = TLV)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heat stress (25) + TOL
Description: 4h exposure to heat (WBGT of 25°C) + Toluene (concentration = TLV)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heat stress (21) + TOL
Description: 4h exposure to heat (WBGT of 30°C) + Toluene (concentration = TLV)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heat stress (21) + ACE
Description: 4h exposure to heat (WBGT of 21°C) + Acetone (concentration = TLV)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heat stress (25) + ACE
Description: 4h exposure to heat (WBGT of 25°C) + Acetone (concentration = TLV)
Study: NCT01103271

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Open-label Placebo
Description: Participants take open-label placebo pills - two twice daily for four weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Open-label Placebo
Description: Participants take open-label placebo pills - two twice daily for four weeks.
Study: NCT03126188

Intervention type: DRUG
Intervention: Sertraline
Description: Tab. Sertraline 50 mg/day, which will be optimized to 75mg/day after 2 weeks if required, and maintained on the same dose for a minimum period of 6 weeks.

Intervention type: DRUG
Intervention: Dosulepin
Description: Tab. Dosulepin 25mg/day, which will be gradually hiked up to 75mg/day over 2 weeks,and the patients will be continued on the same dose for a minimum period of 6 weeks.
Study: NCT02659410

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heat stress (30) + ACE
Description: 4h exposure to heat (WBGT of 30°C) + Acetone (concentration = TLV)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heat stress (21) + DCM
Description: 4h exposure to heat (WBGT of 21°C) + Dichloromethane (concentration = TLV)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heat stress (25) + DCM
Description: 4h exposure to heat (WBGT of 25°C) + Dichloromethane (concentration = TLV)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heat stress (30) + DCM
Description: 4h exposure to heat (WBGT of 30°C) + Dichloromethane (concentration = TLV)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heat stress (21) + TOL (dermal)
Description: 4h exposure to heat (WBGT of 21°C) + Toluene (concentration = TLV), participants breath normal air through a mask for evaluation of dermal absorption.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heat stress (25) + TOL (dermal)
Description: 4h exposure to heat (WBGT of 25°C) + Toluene (concentration = TLV), participants breath normal air through a mask for evaluation of dermal absorption.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heat stress (30) + TOL (dermal)
Description: 4h exposure to heat (WBGT of 30°C) + Toluene (concentration = TLV), participants breath normal air through a mask for evaluation of dermal absorption.
Study: NCT01052194

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: tablet, placebo b.i.d. for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-509
Description: tablets, 25mg b.i.d. for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-509
Description: tablet, 50 mg b.i.d. for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-509
Description: tablet, 100 mg b.i.d. for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-509
Description: tablet, 150 mg b.i.d. for 12 weeks
Study: NCT01095380

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Locomotor training
Description: Locomotor training using body weight support with training on a treadmill or training over ground with differing forms of assistance for stepping

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Locomotor training
Description: Locomotor training using body weight support with training on a treadmill or training over ground with differing forms of assistance for stepping

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Locomotor training
Description: Locomotor training using body weight support with training on a treadmill or training over ground with differing forms of assistance for stepping

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Locomotor training
Description: Locomotor training using body weight support with training on a treadmill or training over ground with differing forms of assistance for stepping
Study: NCT03220204

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PP-based health behavior intervention
Description: The positive psychology exercises include 3 modules: gratitude-based activities, strength-based activities, and meaning-based activities. The goal-setting portion of the program focuses primarily on physical activity (8 weeks) but also includes 4 weeks focusing on diet and medication adherence.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MI-based educational control condition
Description: The MI-based educational program includes information on five topics: (1) information about heart disease and risk factors for worsening heart disease, (2) physical activity, (3) a heart-healthy diet, (4) medication adherence, and (5) stress management.
Study: NCT03834688

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Cycle 1: Venetoclax by mouth daily. The dose will gradually increase during Cycle 1. (Day 1-7: 20 mg; Day 8-14: 50 mg; Day 15-21: 100 mg; Day 22-28: 200 mg.)~Cycles 2-6: Venetoclax 400 mg by mouth daily on Days 1-10 (1 cycle = 28 days).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Cycle 1-6: Bendamustine 90 mg/m² intravenous (IV) on Days 1 and 2 of each cycle. Bendamustine may be started at 70 mg/m² in patients over the age of 75 years with comorbid conditions or patients over the age of 80 years without comorbid conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Cycle 1-6: Rituximab 375 mg/m² IV on Day 1 of each cycle. After 2 consecutive cycles of Rituximab IV are well tolerated, Rituximab may be given subcutaneously.
Study: NCT01684423

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (Xarelto, BAY59-7939)
Description: Subjects were administered with age- and body weight-adjusted oral dose of rivaroxaban (BAY59-7939) IR tablet once daily under fed conditions for 30 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (Xarelto, BAY59-7939)
Description: Subjects were administered with age- and body weight-adjusted oral dose of rivaroxaban (BAY59-7939) IR tablet once daily under fed conditions for 30 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active comparator
Description: Subjects received comparator as per standard of care. The dosage given was to be adjusted based on the individual body weight (low molecular weight heparin, fondaparinux) or international normalized ratio (INR) adjusted (vitamin K antagonist).
Study: NCT04265625

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: endoscopic guidance
Description: Percutaneous tracheotomy performed by endoscopic guidance
Study: NCT01708954

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib S-malate
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib S-malate
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib S-malate
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib Hydrochloride
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib Hydrochloride
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib Hydrochloride
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT03674138

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: DNA-guided choice of therapy
Description: Buccal swab for DNA genotyping to identify best antidepressant therapy

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: DNA-guided choice of therapy
Description: Buccal swab for DNA genotyping to identify best antidepressant therapy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clinical management
Description: Clinical management to identify best antidepressant therapy
Study: NCT02854683

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normal Saline
Description: 1 liter of intravenous saline will be delivered over 1 hour

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral Rehydration Solution
Description: 1 liter of ORS solution given by mouth
Study: NCT00101972

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: monoclonal antibody RAV12
Description: Escalating doses of RAV12 (weekly 0.3, 1.0, 1.5, 3.0, 4.0, 5.0, 6.0 mg/kg or 0.5 mg/kg BIW or TIW; 0.75 mg/kg BIW) for 4 weeks
Study: NCT01975090

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SENTRY IVC Filter
Description: The SENTRY IVC Bioconvertible Filter is designed to provide temporary protection to subjects at transient, high risk of pulmonary embolism. Following conclusion of the protection period The SENTRY filter bioconverts, and filter arms withdraw towards the IVC wall for incorporation; obviating the need for retrieval.
Study: NCT02685605

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard surgery

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intraoperative radiotherapy
Description: Dose to applicator surface: 20-30 Gy; Carl Zeiss INTRABEAM System. IORT with a surface dose of 30 Gy is recommended.Should the proximity to any risk structure not allow to apply 30 Gy, a dose reduction by up to 10 Gy (resulting in a surface dose of 20 Gy) is allowed.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiochemotherapy
Description: EBRT to 60 Gy plus 75 mg/m2/d temozolomide

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiochemotherapy
Description: EBRT to 60 Gy plus 75 mg/m2/d temozolomide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Temozolomide
Description: Adjuvant chemotherapy with 150-200 mg/m2/d temozolomide per cycle (5/28 days).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Adjuvant chemotherapy with 150-200 mg/m2/d temozolomide per cycle (5/28 days).
Study: NCT03467412

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOL-005
Description: intradermal injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOL-005
Description: intradermal injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOL-005
Description: intradermal injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOL-005
Description: intradermal injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: intradermal injection
Study: NCT03179982

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Safe South Africa
Description: Core components of the Safe South Africa intervention include the following:~* Theory driven, best-evidence intervention approaches to adolescent HIV prevention~* Linkages between HIV and IPV~* Victim Empathy~* Healthy Norms Regarding Masculinity~* Bystander Intervention Skills
Study: NCT06287697

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT02116686

Intervention type: DEVICE
Intervention: ventilatory polygraphic recordings
Description: Standard nocturnal in-home ventilatory polygraphic recordings were performed using an Embla device (Embla®, Broomfield, USA) and scored according to the AASM recommendations (RemLogic® software, Broomfield, USA).
Study: NCT00896285

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Large bore chest drain + NSAID based analgesic regimen
Description: Chest tube greater than 14 French size and ibuprofen.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Small bore chest drain + NSAID based analgesic regimen
Description: Chest tube less than or equal to 14 French size and ibuprofen.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Large bore chest drain + opiate based analgesic regimen
Description: Chest tube greater than 14 French size and morphine.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Small bore chest drain + opiate based analgesic regimen
Description: Chest tube less than or equal to 14 French size and morphine.
Study: NCT03216330

Intervention type: OTHER
Intervention: No Intervention
Description: There is no treatment intervention. We are assigning measurement tools such as the Electronic Thimble Algometer for QST and questionnaires to both groups.

Intervention type: OTHER
Intervention: No Intervention
Description: There is no treatment intervention. We are assigning measurement tools such as the Electronic Thimble Algometer for QST and questionnaires to both groups.
Study: NCT03040076

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Bias Treatment
Description: Two computerized tasks will be administered during four intervention sessions. During the first task, the Word Sentence Association Paradigm, participants see a threat or benign word and then an ambiguous sentence. Participants press one if they believe the word and sentence are related and two if they believe the word and sentence are not related. Participants are given feedback that they responded correctly if they state that a benign word is related to the sentence or they state that a threat word is not related to the sentence. The second task is the Ambiguous Scenarios Task. In each trial, an ambiguous scenario, ending in a benign word, appears on the screen. After the scenario is presented, participants respond to a comprehension question and are given feedback on their performance.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Relaxation Condition
Description: Participants assigned to the active control group will complete four sessions of progressive muscle relaxation training. Two alternating relaxation scripts will be used. The scripts will be presented as Youtube videos with a blank black screen and will instruct participants to keep their eyes closed for the duration of the training. Participants will access the videos through Qualtrics to ensure that data can be gathered about their compliance. The relaxation scripts used in the present study will be modified versions of those currently being tested by other researchers utilizing cognitive bias modification paradigms. The relaxation training sessions will be matched to the length of the treatment condition and therefore will last approximately 30 minutes.
Study: NCT05852782

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: White Light therapy
Description: Participants will be exposed to broadband light for one hour
Study: NCT01684423

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active comparator
Description: Subjects received comparator as per standard of care. The dosage given was to be adjusted based on the individual body weight (low molecular weight heparin, fondaparinux) or international normalized ratio (INR) adjusted (vitamin K antagonist).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (BAY59-7939) suspension
Description: Subjects aged were administered with age- and body weight-adjusted oral dose of rivaroxaban (BAY59-7939) suspension under fed conditions twice daily.
Study: NCT04568564

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breathing exercise, intensive spirometry use, supported cough, progressive mobilisation and ambulation
Description: The exercise program includes breathing exercises (chest-abdominal-lateral basal breathing; 10 repetitions), use of intensive spirometry (20 repetitions) and assisted coughing. Apart from this, a progressive mobilization program will be applied considering patient tolerance and hemodynamic parameters, starting after the patient is taken to the service room. The teleconference exercise call will be continued from the postop 1st day until discharge, twice a day.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise booklet
Description: Patients will be interviewed by videoconferencing method at least 1 day before the operation, their first evaluation will be taken and an exercise booklet will be given.